Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2007


HILLSIDE, N.J., Nov. 14, 2007 (PRIME NEWSWIRE) -- Integrated BioPharma, Inc. (Nasdaq:INBP) reported financial results today for its first quarter ended September 30, 2007. Revenues for the quarter ended September 30, 2007 were $12.6 million compared to $12.9 million for the quarter ended September 30, 2006. Operating income for the quarter ended September 30, 2007 was a loss of $1.5 million compared to operating income of $368,000 for the quarter ended September 30, 2006. The Company's increase of $1.8 million in operating losses is primarily attributable to the acquisition it made in its fiscal 2007 third quarter in its Nutraceutical Segment, which resulted in increased selling and administrative costs, including marketing costs, with no significant sales in the current quarter, increased consulting professional fees in its Biotechnologies Segment and an increase in our cost of goods sold in our Pharmaceuticals Segment resulting from increased sales in this segment. As previously announced, the Company expects to spin off its biotech business to the Company's shareholders, after which the biotech business will be separately financed and will operate as a wholly-separate company.

For the quarter ended September 30, 2007, there was a net loss applicable to common shareholders of $1.3 million or ($0.09), compared with a net loss applicable to common shareholders of $514,000, or ($0.04) per diluted share, for the quarter ended September 30, 2006. Net loss applicable to common shareholders is calculated after cash Preferred Stock dividends of $119,000 and non-cash Preferred Stock deemed dividends of $563,000 for the quarter ended September 30, 2006.

A summary of our financial results for the quarter ended September 30, 2007 and 2006 is presented below:


 INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
 (In thousands, except share and per share amounts)
 (Unaudited)

                                            Three Months Ended
                                               September 30,
                                     ------------------------------
                                          2007             2006
                                          ----             ----

 Total revenue                       $     12,626      $     12,911
 Cost of sales                              9,021             8,532
                                     ------------      ------------
 Gross profit                               3,605             4,380
                                     ------------      ------------
 Selling and administrative
  expenses                                  5,064             4,012
                                     ------------      ------------
 Operating (loss) income                   (1,459)              368
 Other expense, net                          (287)              (27)
                                     ------------      ------------
 (Loss) income before income
  taxes and minority interest              (1,746)              341
 Federal and state income
  tax (benefit) expense, net                 (426)              210
                                     ------------      ------------
 Net (loss) income before
  minority interest                        (1,320)              130
 Minority interest                             --                38
                                     ------------      ------------
 Net (loss) income                         (1,320)              168
 Non-cash deemed dividend
  from beneficial conversion
  feature of Series B Preferred
  stock dividend (a)                           --              (563)
 Series B Preferred stock
  dividend (b)                                 --              (119)
                                     ------------      ------------
 Net loss applicable to common
  shareholders                       $     (1,320)     $       (514)
                                     ============      ============

 Net loss per common share:
 Basic                               $      (0.09)     $      (0.04)
                                     ============      ============
 Diluted                             $      (0.09)     $      (0.04)
                                     ============      ============
 Weighted average common
  shares outstanding:
 Basic                                 13,988,647        13,288,078
                                     ============      ============
 Diluted                               13,988,647        13,288,078
                                     ============      ============

 ---------------------------

 (a) Represents non-cash deemed dividend for preferred shareholders
     associated with the amortization of beneficial conversion feature
     and accretion of redemption value of Series B redeemable
     convertible preferred stock.
 (b) Represents 7% dividend on Series B redeemable convertible
     preferred stock.

About Integrated BioPharma, Inc. (INBP)

Integrated BioPharma, Inc. is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company's biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at www.iBioPharma.com.

Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.


            

Contact Data